54660-78-5 Usage
General Description
5-Amino-4-chloropyrimidine is a chemical compound with the molecular formula C4H4ClN3. It is a pyrimidine derivative with a chlorine atom in the fourth position of the pyrimidine ring. 5-AMINO-4-CHLOROPYRIMIDINE is used in various industries, including pharmaceuticals and agrochemicals, as a building block for the synthesis of other organic compounds. It has also been studied for its potential biological and pharmacological properties, including as a potential antiviral and anticancer agent. Additionally, 5-amino-4-chloropyrimidine is used as an intermediate in the synthesis of various pharmaceuticals and as a precursor in the production of herbicides and pesticides. Its versatility and wide range of applications make it an important chemical in the field of organic synthesis and industrial chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 54660-78-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,6,6 and 0 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 54660-78:
(7*5)+(6*4)+(5*6)+(4*6)+(3*0)+(2*7)+(1*8)=135
135 % 10 = 5
So 54660-78-5 is a valid CAS Registry Number.
InChI:InChI=1/C4H4ClN3/c5-4-3(6)1-7-2-8-4/h1-2H,6H2
54660-78-5Relevant articles and documents
Kinase inhibitor, and preparation and application of kinase inhibitor
-
Paragraph 0266-0268; 0271; 0272; 0314; 0317; 0318, (2018/09/11)
The invention provides a compound shown as a formula (I), or a stereoisomer, a tautomer, nitrogen oxide, metabolite, a prodrug, pharmaceutically acceptable salt or solvate of the compound, and application of the compound to preparing drugs or drug compositions for treating Pim kinase-mediated diseases.
Multimeric VLA-4 antagonists comprising polymer moieties
-
Page/Page column 59, (2010/02/15)
Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.